B
Bull
Bull · 25%MRNA
$20.51
Scenario price
$226.380
+10.595 (+4.68%)At close
Loading chart…
- High
- 227.070
- Open
- 217.080
- VWAP
- 221.58
- Volume
- 16.36M
- Mkt Cap
- 46.44B
- Low
- 211.280
- Amount
- 3.62B
- EV/EBITDA, TTM
- -6.35
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
AI analysis of Moderna Inc (MRNA)
BuyModerna Inc is a good buy right now, as it has recently surged 14.21% to a current price of $225 following positive news about a new cancer research initiative. The stock has a strong momentum indicated by an RSI of 77.157, suggesting it is in a bullish trend. However, analysts have mixed views, with targets ranging from $80 to $200, indicating potential volatility. The main risk is the significant insider selling, which has increased by 437.15% over the last quarter, suggesting caution among insiders.
Valuation Metrics
The current forward P/E ratio for Moderna Inc (MRNA) is 23.04, compared to its 5-year average forward P/E of 0.64.
Alphio AI Price Scenarios for MRNA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MRNA
Events Timeline
News
5.010-14CNBCMerck's New Vaccine Manufacturing Accelerates
5.010-14NewsfilterMerck Expects Faster Production of Cancer Vaccine
8.510-14NewsfilterMindWalk Strengthens Development Leadership, Advances Preclinical Research
6.510-13FoolComparative Analysis of Moderna and Vertex Pharmaceuticals
6.510-13FoolModerna vs BioNTech: Diverging Market Performances
MRNA FAQ — answered by Alphio AI
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Moderna Inc is a good buy right now, as it has recently surged 14.21% to a current price of $225 following positive news about a new cancer research initiative. The stock has a strong momentum indicated by an RSI of 77.157, suggesting it is in a bullish trend. However, analysts have mixed views, with targets ranging from $80 to $200, indicating potential volatility. The main risk is the significant insider selling, which has increased by 437.15% over the last quarter, suggesting caution among insiders.
Community
More ↗
$MRNA Moderna appoints Juan Andres as COO Moderna announced the addition of a COO role to support the increasing scale and diversification of the Company. The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader oncology portfolio. The Company has also expanded the infectious disease franchise, which now includes five approved vaccines following the recent U.S. FDA approval of Moderna's seasonal flu vaccine and the European Commission marketing authorization of the Company's seasonal flu plus COVID combination vaccine. Juan Andres will return to Moderna as COO effective October 5. Mr. Andres will report to CEO Stephane Bancel and serve on the Company's Executive Committee. As COO, Mr. Andres will work across the Company to help drive focus, prioritization and execution while leading the manufacturing organization. Moderna also announced that Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, has decided to retire from the Company. Mr. Andres previously spent nearly six years at Moderna, joining the Company in 2017 and serving as Chief Technical Operations and Quality Officer from 2018 through 2022.
Show more
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT
Show moreThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.